Literature DB >> 25724075

A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia.

Taro Kishi1, Yuki Matsuda2, Tomohiko Mukai2, Shinji Matsunaga2, Ichiro Yasue3, Kiyoshi Fujita3, Tomo Okochi4, Shigeki Hirano4, Yusuke Kajio5, Toshihiko Funahashi5, Kaku Akamatsu6, Kei Ino7, Momoko Okuda7, Hideaki Tabuse7, Nakao Iwata2.   

Abstract

We conducted a cross-sectional survey to assess the prevalence of physical pain in Japanese major depressive disorder (MDD) and schizophrenia (SZ) patients as well as in healthy controls (HCs). We also examined the association between their psychopathology and characteristics of pain according to a face-to-face survey by an experienced psychiatrist and psychologist. We analyzed 233 HCs, 94 MDD patients, and 75 SZ patients using the McGill Pain Questionnaire (MPQ) and SF-8 (all participants), the Hamilton Depression Rating Scale 21 items (MDD patients), and the Positive and Negative Symptom Scale (SZ patients). Although MDD patients experienced more pain than HCs, there was no difference in the prevalence of pain between SZ patients and HCs. Moreover, HCs with pain did not have higher SF-8 total scores than those without pain, whereas both MDD and SZ patients with pain had higher SF-8 total scores than those without pain. The severity of psychopathology in MDD and SZ patients was also positively associated with both the prevalence of pain and MPQ scores. MPQ scores were also associated with positive symptoms in SZ patients. Considering these results, physicians need to query MDD patients about physical pain during examination if they are to ensure a favorable and quick response to treatment. The severity of positive symptoms (i.e., clinical status) in SZ patients might also be associated with pain sensitivity, and warrants further investigation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25724075     DOI: 10.1016/j.comppsych.2015.02.004

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  6 in total

1.  A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder.

Authors:  Junaid Asghar; Madiha Tabasam; Maha M Althobaiti; Amal Adnan Ashour; Mohammed A Aleid; Osamah Ibrahim Khalaf; Theyazn H H Aldhyani
Journal:  Front Psychiatry       Date:  2022-05-27       Impact factor: 5.435

2.  An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.

Authors:  Atsushi Kuga; Toshinaga Tsuji; Shinji Hayashi; Mako Matsubara; Shinji Fujikoshi; Hirofumi Tokuoka; Aki Yoshikawa; Rodrigo Escobar; Kazuhide Tanaka; Takaharu Azekawa
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-04       Impact factor: 2.570

3.  Astrocyte Activation in Locus Coeruleus Is Involved in Neuropathic Pain Exacerbation Mediated by Maternal Separation and Social Isolation Stress.

Authors:  Kazuo Nakamoto; Fuka Aizawa; Megumi Kinoshita; Yutaka Koyama; Shogo Tokuyama
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

4.  Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study.

Authors:  Eiji Harada; Yoichi Satoi; Atsushi Kuga; Hirofumi Tokuoka; Toshiaki Kikuchi; Koichiro Watanabe; Levent Alev; Masaru Mimura
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-19       Impact factor: 2.570

5.  Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy.

Authors:  Atsushi Kuga; Tempei Otsubo; Toshinaga Tsuji; Shinji Hayashi; Hideyuki Imagawa; Shinji Fujikoshi; Rodrigo Escobar
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-05       Impact factor: 2.570

6.  Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine.

Authors:  Hirofumi Tokuoka; Makoto Nishihara; Shinji Fujikoshi; Aki Yoshikawa; Atsushi Kuga
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-25       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.